Patients with preformed Abs are at increased risk of rejection after solid organ transplantation; 1 however, the function of Ab-mediated rejection in hematopoietic SCT is still not completely understood. The use of sensitive solidphase Ab detection assays, such as LABScreen (One Lambda, Canoga Park, CA, USA), which are based on flow cytometry, has enhanced our ability to detect and identify donor-specific anti-HLA Abs (DSA). LABScreen Single Antigen (One Lambda) had single recombinant HLA class I and class II Ag on each bead.
This report describes a patient with anti-HLA Abs who achieved successful engraftment after HLA-mismatched cord blood transplantation (CBT) due to primary graft failure after 'mega-dose' PBSC transplantation. Table 1 shows the anti-HLA Abs identified before treatment, and the HLA of the patient and the donors. We identify the epitopes with unique amino-acid positions according to the epitope analysis that was reported by Maruya et al.
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A 40-year-old female developed AML (FAB: M1), which was refractory to two courses of standard induction therapy. There was no available HLA-identical donor in her family or from the Japan Marrow Donor Program. Also, no cord blood with HLA Ags was not reactive to her Abs, which were thought to have been produced during pregnancy. She received PBSC transplantation from a haploidentical child, despite the presence of high-level Abs against the donor-specific Ag (A*2402 and B*5201) in the host-versus-graft reaction. She also displayed strong reactions against many non-donor-specific Ags, which were divided into two groups according to the presence or absence of the epitopes common to A*2402 and B*5201.
After obtaining informed consent from both the patient and donor, the patient received plasmapheresis (on day À16 and À15), rituximab (375 mg/m 2 on day À14) and polyclonal intravenous Ig (i.v. Ig; 0.4 g/kg on day À8, À7 and À6) for reducing Ab levels. 'Mega-dose' transplant of CD34 þ stem cells (14.6 Â 10 6 per kg) was conducted following a conditioning regimen that included of TBI of 12 Gy in four fractions from À10 to À7 and 60 mg/kg CY once daily i.v. on day À4 and À3 (total dose 120 mg/kg), in addition to cytarabine 2 g/m 2 twice daily i.v. on day À6 and À5 (total four doses). Tacrolimus (TAC), short-term MTX and methylprednisolone were given for GVHD prophylaxis. Figure 1 shows the clinical course. Peripheral cytopenia persisted, and primary engraftment failure was diagnosed based on severe BM hypoplasia on day 21. Despite the treatment for reducing Abs, the levels of anti-A*2402, anti-B*5201 and non-DSA sharing epitopes common to A*2402 and B*5201 remained very high. In contrast, the levels of Abs without those epitopes, such as A*2601, decreased rapidly.
CBT was performed from the two HLA-Ag-mismatched (A26, B46) cord blood graft 32 days after PBSC transplantation, because the Ab level against A*2601, which was present in the cord blood, was observed to have significantly decreased. The preparative regimen consisted of fludarabine 30 mg/m 2 once daily i.v. on day À5 to À2 (total dose 120 mg/m 2 ) and L-phenyl-alanine mustard 50 mg/m 2 once daily i.v. on day À3 and À2 (total two doses). Prophylaxis for GVHD was TAC and short-term MTX. She received a cord blood infusion containing 3.36 Â 10 7 nucleated cells per kg. Primary engraftment with neutrophils 40.5 Â 10 9 per l and complete donor chimerism by sex chromosome were achieved on day 25 after CBT. She has since remained in CR for 11 months after CBT without any GVHD even after the discontinuation of TAC. The Ab levels against most of the Ag including A*2601 were not detectable after engraftment. On the contrary, anti-A*2402, anti-B*5201 and non-DSA sharing epitopes common to A*2402 and B*5201 increased and remained high.
The mechanism for the rejection of PBSCs in this case has not yet been clearly elucidated. A marked increase of anti-A*2402 and anti-B*5201 levels, however, suggested that the most likely mechanism could be the host-mediated humoral response. Sensitization to HLA Ags increases the risk of graft failure in Allo-SCT. 3, 4 Plasmapheresis, i.v. Ig, and rituximab are commonly used in solid organ transplantation for the abrogation of allo-Ab-mediated rejection. 5, 6 Indeed, these were sufficient in our case to reduce the levels of the Abs not sharing epitopes with A*2402 and B*5201. However, these had no more effect than to hold the increase in anti-A*2402 and anti-B*5201 levels down to within the specified time. These procedures failed to cause the apoptosis of plasma cells in vitro, thereby preventing allo-Ab production. 7 Donor platelet transfusion is another procedure to eliminate DSA. 8 However, it could not be conducted in this case because the patient had experienced severe nonhemolytic transfusion reactions to random pooled plts. In addition to allo-Ab-mediated rejection, there is no denying that the absence of a killer Ig-like receptor 2DL ligand mismatch may have contributed to the graft failure observed in this case. This is because killer Iglike receptor ligand incompatibility in the graft-versus-host direction has been suggested to reduce graft failure risk in haploidentical hematopoietic SCT.
Although anti-HLA Ab remained after the PBSC transplantation, the reduced anti-A*2601 level allowed for the successful engraftment after HLA-mismatched CBT. Kataoka et al. 9 also reported two cases of CBT similar to ours.
The levels of only anti-A*2402, anti-B*5201 and non-DSA sharing their common epitopes remained high, which suggests that epitope sharing between unrelated HLA molecules was the mechanism underlying DSA and non-DSA generation. In renal transplantation, epitope matching could be better than Ag matching for avoiding the development of Abs, 10 whereas in hematopoietic SCT epitope matching could not improve transplant 
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Donor and recipient HLA were identified by high-resolution typing. The results have been reported as the mean fluorescence intensity (MFI) and the cutoff value was 1000 MFI. In this case, fluorescence values of the negative control beads were below 100 and the ratio of positive control to negative control beads was over 100. Some sample data did not fit these conditions. The sera were cleaned, using Adsorb Out to reduce the background fluorescence. Abs against HLA-C and DR were not detected. Numbers (1) (2) (3) (4) (5) indicate epitopes common to A*2402 and B*5201. Unique position and amino acid is denoted by a three-digit number that pinpoints the position on the HLA molecule. This is followed by a single letter that stands for a particular amino acid.
(1), 73T, 76E and 77N; (2), 76E, 77N and 80I; (3), 79R and 80I; (4), 80I and 90A; (5), 82L and 83R. outcome. In addition, epitope matching remains difficult because epitopes are often not in linear sequences. However, mismatching at the immunogenic amino-acid positions has been reported to not always result in Ab production, and the differences between producer and nonproducer were due to the efficiency of HLA class II alleles in presenting the mismatched alleles. This finding indicates that full epitope matching is therefore not required, and the hematopoietic SCT outcome might thus improve. 2 The persistence of the anti-donor immune response suggests the existence of the residual host hematopoietic cell. Therefore, monitoring of anti-HLA Ab serves as a sensitive method in detection of minimal residual disease.
Identifying acceptable HLA Ag mismatches might be useful to achieve engraftment after HLA-mismatched SCT for allosensitized patients. In addition, this case suggests that epitope matching might be more effective than Ag matching.
